Correlation Between Lineage Cell and Replimune

Can any of the company-specific risk be diversified away by investing in both Lineage Cell and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lineage Cell and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lineage Cell Therapeutics and Replimune Group, you can compare the effects of market volatilities on Lineage Cell and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lineage Cell with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lineage Cell and Replimune.

Diversification Opportunities for Lineage Cell and Replimune

0.72

Correlation Coefficient

Lineage Cell  Replimune

Poor diversification

The 3 months correlation between Lineage and Replimune is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Lineage Cell Therapeutics and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Lineage Cell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lineage Cell Therapeutics are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Lineage Cell i.e., Lineage Cell and Replimune go up and down completely randomly.

Pair Corralation between Lineage Cell and Replimune

Given the investment horizon of 90 days Lineage Cell Therapeutics is expected to generate 1.35 times more return on investment than Replimune. However, Lineage Cell is 1.35 times more volatile than Replimune Group. It trades about 0.02 of its potential returns per unit of risk. Replimune Group is currently generating about -0.05 per unit of risk. If you would invest  50.00  in Lineage Cell Therapeutics on December 30, 2024 and sell it today you would lose (1.00) from holding Lineage Cell Therapeutics or give up 2.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Lineage Cell Therapeutics  vs.  Replimune Group

Lineage Cell Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lineage Cell Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Lineage Cell may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Replimune Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Replimune Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Lineage Cell and Replimune

The main advantage of trading using opposite Lineage Cell and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lineage Cell position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.

The idea behind Lineage Cell Therapeutics and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.